Delta, Kelowna, BC – May 11, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #563, Cannabis News and Stocks on the Move; (CSE: XTRX), (TSXV: KHRN) (OTCQX: KHRNF), (CSE: CURA) (OTCQX: CURLF), (CSE: DELC) (OTCQB: DELFC), (OTC: MJNA)
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
In today’s podcast we look at a few public company announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, applauds the publication today in the accredited scientific journal “Psychopharmacology” of the first findings arising from Project Twenty 21, UK’s first and largest national medical cannabis registry that was launched on November 7, 2019 at the Royal College of Psychiatrists in London.
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, monitored by Drug Science, UK’s leading independent scientific body. The project aims to create the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis to warrant NHS funding where the benefits of treatment with medical cannabis are proven to outweigh the potential risks.
The Project Twenty 21 study has now licensed prescriptions of medical cannabis to over 900 patients who are in substantially poorer health than the general population, and who have been unable to manage their diagnosed conditions with commonly prescribed medicines. The findings show that legally prescribed cannabis provides clinically significant improvements in the quality of life of patients living with conditions such as Chronic Pain, Multiple Sclerosis, Tourette’s Syndrome, Epilepsy and Post Traumatic Stress Disorder (PTSD). Based on the early positive momentum of the Project Twety21, Khiron will be launching other commercial initiatives to reach as many people as possible in the country.
The patient data collected show that medical cannabis improves the quality of life more than classical treatments do, for example for neuropathic pain. According to the National Institute for Clinical Excellence (NICE), there is little or no evidence that commonly prescribed drugs, such as benzodiazepines or opioids, make any difference to people’s quality of life, pain or psychological distress, but they can cause harm, including possible addiction. In contrast, the results of Project Twenty21 clearly show a fifty percent increase in patients’ self-reported health and ability to lead a more normal life as well as significant improvements in patients’ ability to manage debilitating secondary conditions such as anxiety, insomnia and depression. Also, patients are now able to avoid criminality with legal prescriptions, as many have felt compelled to turn to illegal use to manage their conditions.
Project leader of Twenty21 Professor David Nutt from Drug Science, comments: “A lack of clinical evidence has made it difficult for doctors to confidently prescribe legal medical cannabis in the UK. These new findings provide a major step forward and help to clarify the benefit these medicines can have for thousands of seriously ill patients.”
Tejinder Virk, President of Khiron Europe, says: “We are glad to see our strong commitment with medical research bear its fruits with this publication. Khiron is a true pioneer in the medical cannabis landscape in the UK, and not just because of its products. Our biggest contribution to improve access to medical cannabis in the UK is our education programs for prescribing clinicians and the dissemination of our expertise with cannabis-based therapeutics. We plan to continue our data-driven approach with the deployment of EU-GMP cannabinoid-based medicines based on our Colombian extracts, whose efficacy and safety are backed by clinical data collected in our wholly-owned clinics with over 17,000 prescriptions.”
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (“Adven”) has launched its own range of medical cannabis products in Germany, Europe’s largest medical cannabis market. The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THC/CBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2025.
Antonio Costanzo, CEO of Curaleaf International, said, “We are very pleased to bring our first medical cannabis products to market in Germany and, with the rapid extension of our product range in 2021, establishing ourselves as a leader in Europe’s largest medical cannabis market. Curaleaf International’s European supply chain, from cultivation to product research and development and EU-GMP manufacturing processes across Europe, means we are able to guarantee a consistency of product and price to clinicians and patients in need of the highest quality medical cannabis.”
Julian Vaterrodt, Managing Director, Adven GmbH, added, “German patients and practitioners are increasingly demanding high-quality, consistent and reliable European natural alternatives to help manage a wide range of complaints. Adven is committed to providing a differentiated product and service for the German market. We focus on providing a consistent supply of high-quality European medical cannabis and cutting-edge digital technologies to improve the patient and healthcare professional experience.”
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELFC) a psychedelic wellness platform, announced that its acquisition target (under binding letter agreement see news release dated February 4, 2021), Ketamine Infusion Centers (“KIC”), proposes to acquire two (2) additional licensed ketamine clinics in Arizona. The proposed acquisition would double the footprint of the infusion chain and become the largest operator in the state of Arizona.
“This is a major step toward becoming the largest ketamine clinic operator in the country, bringing superior quality and expanding access for patients,” said Matt Stang, Delic CEO and co-founder. “KIC is the leading name in high quality care and incredible outcomes for its patients and this move helps grow that reputation significantly. As a vital part of the Delic platform, KIC will continue to offer wellness and benefits for many people suffering from anxiety, depression and PTSD.”
Over the past three years, the team at KIC has expanded from Arizona to California, while overseeing 4,000 treatments administered to date, and generating more than $1.5-million (U.S.) in revenue. KIC continues to operate under the Delic umbrella, under the direction and guidance of Dr. Christopher Ray, Sonny Diaz, Rogelio Monzon and Ganesh Acharya. With the successful completion of the acquisition, KIC will expand to 3 clinics in Arizona, with locations in Central Phoenix, East Valley, and West Valley, and 1 in California, with a location in Bakersfield.
Sonny Diaz, co-founder of KIC, stated: “We are thrilled to join the Delic family and double our footprint with this acquisition, allowing greater access to patients for these vital services. Ketamine Infusion Centers unique model and passion to obtain the highest patient outcomes and purely evidence-based practices is a perfect fit in the Delic ecosystem. Together with their vast knowledge of psychedelic wellness, strong partner channels and mission to bring psychedelic wellness into the mainstream, we see unlimited potential of how many lives we may positively affect together.”
As part of these two sublease transactions, KIC will assume ownership of both licences, which contain the OTC licenses for the respective locations at no additional costs. KIC will submit the necessary paperwork to the State of Arizona to complete the license transfer processes.
Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds(R) Brasil had its best revenue month ever in Company history in April 2021.
“Our HempMeds Brasil operations have seen a consistent increase over the years. We aim to reach as many consumers in need as possible and last month’s achievements prove that we are continuing to expand our reach to our target audiences,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.
“I am incredibly proud of the success our HempMeds Brasil team has been able to achieve. As we celebrate our best revenue month in company history, we are scaling our operations in the country, refreshing our consumer-facing website and increasing the size of our facilities in Brazil to meet the needs of our expanding team,” said HempMeds(R) CEO Raul Elizalde.
“In the coming months, to support our continued growth, we intend to partner with the largest higher education institution in Brazil to educate medical professionals on the potential benefits of cannabidiol (CBD) and are moving forward in securing partnerships with well-respected professional and Olympic athletes,” said HempMeds(R) Brasil Managing Director Matheus Patelli. “My team has successfully been able to show Brazilian citizens that our products are of the highest quality and trustworthy, just like the people who work at the Company.”
Once again, today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android